KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis

Experimental and Molecular Medicine

Volumn 38, Issue 5, 2006, Pages 502-508

  Yi, Eui Yeun ^a   Park, Shi Young ^a   Hyun, Seok Song ^a,b   Myung, Jin Son ^a,b   Yi, Kyu Yang ^c   Yoo, Sung En ^c   Kim, Yung Jin ^a  

^a Pusan National University   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Angiogenesis; Angiogenesis inhibitors; Fibroblast growth factor 2; Neoplasms

Indexed keywords

ANGIOGENESIS INHIBITOR; BASIC FIBROBLAST GROWTH FACTOR; BENZOPYRAN DERIVATIVE; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GELATINASE A; KR 31831; MATRIGEL; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COW; DRUG EFFECT; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

BOS TAURUS;

EID: 33750743727     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2006.59     Document Type: Article

References (18)

1. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 1997;22:251-6
2. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57
3. Drabkin DS, Ausin JH. Spectrophotomeric constans for common hemoglobin derivaties in human, dog, and rabbit blood. J Biol Chem 1932;98:719
4. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994;79:185-8
5. Folkman J, Haudenschild C. Angiogenesis in vitro. Nature 1980;288:551-6
6. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6
7. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-4
8. Giavazzi R, Taraboletti G. Preclinical development of metalloproteasis inhibitors in cancer therapy. Ciritical Rev Oncol/Hematol 2001;37:53-60
9. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005;23:3243-56
10. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39
11. Kim NJ, Lee SK, Yi YK, Yoo SE, Kim GC, Lee CO, Park SH, Lee BH. Identification of a novel aniangiogenic agent; 4-(N-imidazol-2-ylmethyl)amino benzopyran analogues. Bioorg Med Chem Lett 2003;13:1661-3
12. Lee MS, Moon EJ, Lee SW, Kim MS, Kim KW, Kim YJ. Angiogenic activity of pyruvic acid in in vivo and in vitro angiogenesis models. Cancer Res 2001;61:3290-3
13. Liekens S, Clercq ED, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharm 2001;61:253-70
14. Miao RQ, Agata J, Chao L, Chao J. Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood 2002;100:3245-52
15. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR. A simple, quantitative method for assessing antiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Investig 1992;67:519-28
16. Savani RC, Cao G, Pooler PM, Zaman A, Zhou Z. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J Biol Chem 2001;276:36770-8
17. Siddiqui FA, Desai H, Siddiqui TF, Francis JL. Hemoglobin induces the expression and secretion of vascular endothelial growth factor from human malignant cells. Hematol J 2002;3:264-70
18. ATP) opener without vasorelaxation: N-(6-aminobenzopyranyl)-N′- benzyl-N″cyanoguanidine. J Med Chem 2001;44:4207-15